|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
01.06.26 - 07:09
|
Idorsia reports new positive results with its breakthrough C. difficile vaccine – underscoring the unique potential of its glycan technology (GlobeNewswire EN)
|
|
|
Allschwil, Switzerland – June 1, 2026Idorsia Ltd (SIX: IDIA) today announced additional positive clinical results for IDOR-1134-2831, its vaccine targeting Clostridioides difficile (C. difficile) in a Phase 1 clinical pharmacology trial. The glycan target of this vaccine is present on both bacteria and spores – the transmissible form of the pathogen responsible for spreading infection – of the most clinically relevant C. difficile strains, including hypervirulent variants. Following initial results in June 2025, which provided the first clinical validation for Idorsia's synthetic glycan vaccine technology, the company advanced the program with a higher-dose cohort....
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
10.04.26 - 07:03
|
Idorsia issues invitation to the 2026 Annual General Meeting of Shareholders (GlobeNewswire EN)
|
|
|
Allschwil, Switzerland – April 10, 2026Idorsia Ltd (SIX: IDIA) today issued the invitation to the upcoming Annual General Meeting (AGM) of Shareholders on behalf of the Board of Directors. The meeting to approve the Annual Report of the year ending December 31, 2025, will be held on Wednesday, May 6, 2026, at 14.00 CEST at the Congress Center, Messe Basel, Switzerland....
|
|
|
09.04.26 - 07:48
|
Idorsia ernennt Amer Joseph zum neuen Chief Medical Officer (Cash)
|
|
|
- Idorsia hat Amer Joseph zum Chief Medical Officer und Leiter der globalen klinischen Entwicklung ernannt. Er tritt die Nachfolge von Alberto Gimona an, der in den Ruhestand geht. Joseph übernimmt die neue Position ab dem 1. Mai 2026, wie das Biopharma-Unternehmen am Donnerstag mitteilte....
|
|
|
|
Börsentreff auf Facebook |
Börsentreff auf X |
Börsentreff auf Instagram
